Skip to main content
SpringerLink
Log in

Typhoid Vaccines

  • Chapter
New Bacterial Vaccines

Part of the book series: Medical Intelligence Unit ((MIUN))

  • 169 Accesses

Abstract

Typhoid fever is a systemic illness caused by infection with the Gram negative bacterium Salmonella enterica sub-species 1 serovar Typhi (S. typhi). Patients with typhoid fever can be broadly divided into two groups, those with ‘mild’ disease (uncomplicated typhoid fever) and those with complications. The signs and symptoms of uncomplicated typhoid fever are relatively nonspecific, and their reported frequency is highly variable. The classic symptoms are pyrexia, headache and abdominal pain or discomfort. Fever rises in a step-wise manner during the first week of illness and can be as high as 40°C1,2 The disease is self-limiting in most patients and resolves within 4–5 weeks in the absence of chemotherapy1 Patients given a course of an appropriate antibiotic can recover within a week although weakness and debilitation may persist for several months.3,4

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Huckstep RL. Typhoid fever and other salmonella infections. London: E & S Livingstone Ltd, 1962.

    Google Scholar 

  2. Hornick RB, Greisman SE, Woodward TF et al. Typhoid fever: pathogenesis and immunologic control (first of two parts). New Eng J Med 1970; 283:686–691

    Article  PubMed  CAS  Google Scholar 

  3. Smith MD, Duong NM, Hoa NT et al. Comparison of ofloxacin and ceftriaxone for short-course treatment of enteric fever. Antimicrob Agents Chemother 1994; 38:1716–1720.

    Article  PubMed  CAS  Google Scholar 

  4. Forsyth JRL. Typhoid and paratyphoid. In: Topley, Wilson, eds. 9th ed. Vol 3, Chp 24. 1998: 459–478.

    Google Scholar 

  5. Bitar R, Tarpley J. Intestinal perforation in typhoid fever: a historical state-of-the-art review. Rev Infect Dis 1985; 7:257–271.

    Article  PubMed  CAS  Google Scholar 

  6. Butler T, Knight J, Nath SK et al. Typhoid fever complicated by intestinal perforation: a persisting fatal disease requiring surgical management. Rev Infect Dis 1985; 7:244–256

    Article  PubMed  CAS  Google Scholar 

  7. van Basten JP, Stockenbrugger R. Typhoid perforation. A review of the literature since 1960. Trop Geog Med 1994; 46:336–339.

    Google Scholar 

  8. Azad AK, Islam R, Salam MA et al. Comparison of clinical features and pathological findings in fatal cases of typhoid fever during the initial and later stages of the disease. Am J Trop Med Hyg 1997; 56:490–493.

    PubMed  CAS  Google Scholar 

  9. Butler T, Islam A, Kabir I et al. Patterns of morbidity and mortality in typhoid fever dependent on age and gender: review of 552 hospitalised patients with diarrhoea. Rev Infect Dis 1991; 13:85–90.

    Article  PubMed  CAS  Google Scholar 

  10. Stuart BM, Pullen RL. Typhoid. Clinical analyses of three hundred and sixty cases. Arch Internal Med. 1946; 78:629–661.

    Article  CAS  Google Scholar 

  11. Miller SI, Hohmann EL, Pegues DA. Salmonella (including Salmonella typhi). In: Mandell GL, Bennettt JR, Dolin R, eds. Principles and Practice of Infectious Diseases. Chpt 200. 1994:2013–2033. Churchill Livingstone, New York.

    Google Scholar 

  12. Edelman R, Levine MM. Summary of the international workshop on typhoid fever. Rev Inf Dis 1986; 4:329–349.

    Article  Google Scholar 

  13. Ivanhoff B. Typhoid fever: global situation and WHO recommendations. Southeast Asian J Trop Med Pub Health. 1995; 26(2):l-6.

    Google Scholar 

  14. Sinha A, Sazawal S, Kumar R et al. Typhoid fever in children aged less than 5 years. Lancet 1999; 354:734-737.

    Article  PubMed  CAS  Google Scholar 

  15. Ferreccio C, Levine MM, Manterola A. Benign bacteremia caused by Salmonella typhi and paratyphi in children younger than 2 years. J Pediatrics 1984; 104:899-901.

    Article  CAS  Google Scholar 

  16. Galloway H, Clark NS, Blackhall M. Paediatric aspects of the Aberdeen typhoid outbreak. Arch Dis Child 1966; 41:63-68.

    Article  PubMed  CAS  Google Scholar 

  17. Birkhead GS, Morse DL, Levine WC. Typhoid fever at a resort hotel in New York: a large outbreak with an unusual vehicle. J Infect Dis 1993; 167:1228-1232.

    Article  PubMed  CAS  Google Scholar 

  18. Wain J, Hoa NT, Chinh NT et al. Quinolone-resistant Salmonella typhi in Viet Nam: molecular basis of resistance and clinical response to treatment. Clin Infect Dis 1997; 25:1404–1410.

    Article  PubMed  CAS  Google Scholar 

  19. Bodhidatta L, Taylor DN, Thisyakorn U. Control of typhoid fever in Bangkok, Thailand, by annual immunization of schoolchildren with parenteral typhoid vaccine. Rev Inf Dis 1987; 9:841–845.

    Article  CAS  Google Scholar 

  20. Tacket CO, Levine MM. Human typhoid vaccines - old and new. In: DAA Ala’Aldeen, CE Hormaeche, eds. Molecular and Clinical Aspects of Bacterial Vaccine Development. England: John Wiley and Sons, 1995:119–178.

    Google Scholar 

  21. Lindberg AA. Vaccination against enteric pathogens: from science to vaccine trials. Curr Opin Microbiol 1998; 1:116–24.

    Article  PubMed  CAS  Google Scholar 

  22. Hornick RB, Greisman SE, Woodward TF et al. Typhoid fever: pathogenesis and immunologic control (second of two parts). New Eng J Med 1970; 283:739–746.

    Article  PubMed  CAS  Google Scholar 

  23. Cvjetanovic B, Uemura K. The present status of field and laboratory studies of typhoid fever and paratyphoid vaccines. Bull WHO 1965; 32:29–36.

    PubMed  CAS  Google Scholar 

  24. Yugoslav Typhoid Commission. A controlled field trial of the effectiveness of acetone-dried and inactivated and heat-phenol-inactivated typhoid vaccines in Yugoslavia. Bull WHO 1964; 30:623–630.

    Google Scholar 

  25. Ashcroft MT, Singh B, Nicholson CC et al. A seven-year field trial of two typhoid vaccines in Guyana. Lancet 1967; 2:1056–1059.

    Article  PubMed  CAS  Google Scholar 

  26. Polish Typhoid Committee. Controlled field trials and laboratory studies on the effectiveness of typhoid vaccines in Poland 1961–1964. Bull WHO 1966; 34:211–222.

    Google Scholar 

  27. Hejfec LB, Salmin LV, Lejtman MZ et al. A controlled field trial and laboratory study of five typhoid vaccines in the USSR. Bull WHO 1966; 34:321–339.

    PubMed  CAS  Google Scholar 

  28. Ivanhoff B, Levine MM Lambert PH. Vaccination against typhoid fever: present status. Bull WHO 1994; 72:957–971.

    Google Scholar 

  29. Felix A, Pitt RM. A new antigen of B. typhosus. Lancet 1934; July: 186–191

    Google Scholar 

  30. Robbins, JD, Robbins JB. Reexamination of the protective role of the capsular polysaccharide (Vi antigen) of Salmonella typhi. J Infect Dis 1984; 150:436–49.

    Article  PubMed  CAS  Google Scholar 

  31. Liu SH, Sanderson KE. Rearrangement in the genome of the bacterium Salmonella typhi. Proc Natl Acad Sei USA 1995; 92:1018–22.

    Article  CAS  Google Scholar 

  32. Arricau N, Hermant D, Waxin H et al. The RcsB-RcsC regulatory system of Salmonella typhi differentially modulates the expression of invasion proteins, flagellin and Vi antigen in response to osmolarity. Mol Microbiol 1998; 29:835–850.

    Article  PubMed  CAS  Google Scholar 

  33. Pickard D, Li J, Roberts M et al. Characterisation of defined ompR mutants of Salmonella typhi: ompR is involved in the regulation of Vi polysaccharide expression. Infect Immun 1994; 62:3984–3993.

    PubMed  CAS  Google Scholar 

  34. Landy M. Studies on Vi antigens: immunization of human beings with purified Vi antigen. Am J Hyg 1954; 60:52–62.

    PubMed  CAS  Google Scholar 

  35. Wong KH, Freeley JC. Isolation of Vi antigen and a simple method for its measurement. App Microbiol 1972; 24:628–633.

    CAS  Google Scholar 

  36. Szewczyk B, Taylor A. Immunochemical properties of Vi antigen from Salmonella typhi Ty2: presence of two antigenic determinants. Infect Immun 1980; 29:539–544.

    PubMed  CAS  Google Scholar 

  37. Tacket CO, Ferreccio C, Robbins JB et al. Safety and immunogenicity of two Salmonella typhi Vi capsular polysaccharide vaccines. J Infect Dis 1986; 154:342–345.

    Article  PubMed  CAS  Google Scholar 

  38. Acharya IL, Lowe CU, Thapa R et al. Prevention of typhoid fever in Nepal with the Vi capsular polysaccharide of Salmonella typhi. A preliminary report. N Eng J Med 1987; 29:1101–1104.

    Article  Google Scholar 

  39. Klugman KP, Gilbertson IT, Koornhof HJ et al. Protective activity of Vi capsular polysaccharide vaccine against typhoid fever. Lancet 1987; 2:1165–1169.

    Article  PubMed  CAS  Google Scholar 

  40. Klugman, KP, Koornhof HJ, Robbins JB et al. Immunogenicity, efficacy and serological correlate of protection of Salmonella typhi Vi capsular polysaccharide vaccine three years after immunisation. Vaccine 1996; 14:435–438.

    Article  PubMed  CAS  Google Scholar 

  41. Germanier R, Furer E. Isolation and characterisation of a galE mutant Ty21a of Salmonella typhi: a candidate strain for a live oral vaccine. J Infect Dis 1975; 131:553–558.

    Article  PubMed  CAS  Google Scholar 

  42. Silva BA, Gonzalez C, Mora GC et al. Genetic characteristics of the Salmonella typhi strain Ty21a vaccine. J Infect Dis 1987; 155:1077.

    Article  PubMed  CAS  Google Scholar 

  43. Cryz SJ, Furer E. Further characterisation of the Salmonella typhi Ty21a vaccine strain. J Infect Dis 1988; 157:1276–1277.

    Article  PubMed  CAS  Google Scholar 

  44. Wahdan MH, Cerisier SY, Sallam S et al. A controlled field trial of live Salmonella typhi strain Ty21a oral vaccine against typhoid: three-year results. J Infect Dis 1982; 145: 292–295.

    Article  PubMed  CAS  Google Scholar 

  45. Levine MM, Ferrecio C, Black RE et al. Large-scale field trial of Ty21a live oral typhoid vaccine in enteric-coated capsule formulation. Lancet 1987; 1049–1052.

    Google Scholar 

  46. Hone DM., Attridge SR, Forrest B et al. A galE via (Vi antigen-negative) mutant of Salmonella typhi Ty2 retained virulence in humans. Infect Immun 1988; 56:1326–1333.

    PubMed  CAS  Google Scholar 

  47. The Chilean Typhoid Committee, Black RE, Levine MM et al. Efficacy of one or two doses of Ty21a Salmonella typhi vaccine in enteric-coated capsules in a controlled field trial. Vaccine 1990; 8:81–84.

    Article  Google Scholar 

  48. Ferreccio C, Levine MM, Rodriguez H et al. Comparative efficacy of two, three, or four dooses of Ty21a live oral typhoid vaccine in enteric-coated capsules: a field trial in an endemic area. J Infect Dis 1989; 159:766–769.

    Article  PubMed  CAS  Google Scholar 

  49. Levine MM, Ferreccio C, Cryz S et al. Comparison of enteric-coated capsules and liquid formulation of Ty21a typhoid vaccine in randomised controlled field trial. Lancet 1990; 336:891–894.

    Article  PubMed  CAS  Google Scholar 

  50. Simanjuntak CH, Paleologo FP, Punjabi NH et al. Oral immunisation against typhoid fever in Indonesia with Ty21a vaccine. Lancet 1991; 338:1055–1059.

    Article  PubMed  CAS  Google Scholar 

  51. Levine MM, Ferreccio C, Abrego P et al. Duration of efficacy of Ty21a, attenuated Salmonella typhi live oral vaccine. Vaccine 1999; 17:S22–S27.

    Article  PubMed  Google Scholar 

  52. Yokoyama H, Ikedo M, Kohbata S et al. An ultrastructural study of HeLa cell invasion with Salmonella typhi GIFU 10007. Microbiol Immunol. 1986; 31:1–11.

    Google Scholar 

  53. Huang XZ, Tall B, Schwan WR et al. Physical limitations on Salmonella typhi entry into cultured human intestinal epithelial cells. Infect Immun 1998; 66:2928–2937.

    PubMed  CAS  Google Scholar 

  54. Esposito M. Agar plaque formation by mouse spleen cells in response to vaccination with Vi antigen in typhoid vaccines. J Bacteriol 1969; 99:356–357.

    PubMed  CAS  Google Scholar 

  55. Looney RJ, Steigbigel RT. Role of the Vi antigen of Salmonella typhi in resistance to host defence in vitro. J Lab Clin Med 1986; 108:506–16.

    PubMed  CAS  Google Scholar 

  56. Jiminez-Lucho V, Leive LL, Joiner KA. Role of the O-antigen of lipopolysaccharide in Salmonella in protection against complement action. In: BH Inglewski, Clark VL, eds. Molecular Basis of Bacterial Pathogenesis: The Bacteria. Volume XL Academic Press, 1990.

    Google Scholar 

  57. Casadevall A. Antibody-mediated protection against intracellular pathogens. Trend Microbiol. 1998; 6:102–107.

    Article  CAS  Google Scholar 

  58. Chaicumpa W, Wechsathanarak Y, Tantivanich S et al. Antibody responses to heat-killed, phenol preserved parenteral typhoid vaccines. Southeast Asian J Trop Med Public Health 1985; 16:371–376.

    PubMed  CAS  Google Scholar 

  59. Wahdan MH, Sippel JE, Mikhail IA et al. Controlled field trial of a thoid vaccine prepared with a nonmotile mutant of Salmonella typhi Ty2. Bull WHO 1975; 52:69–72.

    PubMed  CAS  Google Scholar 

  60. Mond JJ, Lees A, Snapper CM. T-cell independent antigens type 2. Annul Rev Immunol 1995; 13:655–692.

    Article  CAS  Google Scholar 

  61. Szu SC, Taylor DN, Trofa AC et al. Laboratory and preliminary clinical characterisation of Vi capsular polysaccharide-protein conjugate vaccines. Infect Immun 1994; 62:4440–4444.

    PubMed  CAS  Google Scholar 

  62. Kroon FP, van Dissel JT, Ravensbergen E et al. Impaired antibody response after immunisation of HIV-infected individuals with the polysaccharide vaccine against Salmonella typhi (Typhim-Vi“). Vaccine 1999; 17:2941–2945.

    Article  PubMed  CAS  Google Scholar 

  63. Tackett CO, Levine MM, Robbins JB. Persistence of antibody titres three years after vaccination with Vi polysaccharide vaccine against typhoid fever. Vaccine 1988; 6:307–308.

    Article  Google Scholar 

  64. Viret JF, Favre D, Wegmuller B et al. Mucosal and systemic immune responses in humans after primary and booster immunizations with orally administered invasive and noninvasive live attenuated bacteria. Infect Immun 1999; 67:3680–3685.

    PubMed  CAS  Google Scholar 

  65. Forrest BD. Identification of intestinal immune response using peripheral blood lymphocytes. Lancet 1988; 81–83.

    Google Scholar 

  66. Kantele A, Arvilommi H, Kantele JM et al. Comparison of the human immune response to live oral, killed oral or killed parenteral Salmonella typhi Ty21a vaccine. Microb Pathogen 1991; 10:117–126.

    Article  CAS  Google Scholar 

  67. Kantele A, Kantele JM, Savilahti E et al. Homing potentials of circulating lymphocytes in humans depends on the site of activation. Oral but not parenteral, typhoid vaccination induces circulating antibody-secreting cells that all bear homing receptors directing them to the gut. J Immunol 1997; 158:574–579.

    PubMed  CAS  Google Scholar 

  68. D’Amelio R, Tagliabue A, Nencioni L et al. Comparative analysis of immunological responses to oral (Ty21a) and parenteral (TAB) typhoid vaccines. Infect Immun 1988; 56:2731–2735.

    PubMed  Google Scholar 

  69. Tagliabue A, Villa L, de Magistris MT et al. IgA-driven T cell mediated anti-bacterial immunity in man after live oral Ty21a vaccine. J Immunol 1986; 137:1504–1510.

    PubMed  CAS  Google Scholar 

  70. Levine MM, Taylor DN, Ferrecio C. Typhoid vaccines come of age. Pediatr Infect Dis J 1989; 8:374–381.

    Article  PubMed  CAS  Google Scholar 

  71. Levine MM. Presented at the Third Asia-Pacific Symposium on Typhoid Fever and Other Salmonellosis, Denpasar, Bali, Indonesia. 1997; December 8–10.

    Google Scholar 

  72. Murphy JR, Grez L, Schlesinger L et al. Immunogenicity of Salmonella typhi Ty21a vaccine for young children. Infect Immun 1991; 59:4291–4293.

    PubMed  CAS  Google Scholar 

  73. Cryz SJ, Vanprapar N, Thisyakorn U et al. Safety and immunogenicity of Salmonella typhi Ty21a vaccine in young Thai children. Infect Immun 1993; 61:1149–1151.

    PubMed  Google Scholar 

  74. Kossacza Z, Bystricky S, Bryla DA et al. Synthesis and immunological properties of Vi and Di-O-acetyl pectin protein conjugates with adipic acid dihydrazide as the linker. Infect Immun 1997; 65:2088–2093.

    Google Scholar 

  75. Kossaczka Z, Lin FYC, Ho VA et al. Safety and immunogenicity of Vi conjugate vaccines for typhoid fever in adults, teenagers, and 2- to 4-year old children in Vietnam. Infect Immun 1999; 67:5806–5810.

    PubMed  CAS  Google Scholar 

  76. Lin FYC, Ho VA, Khiem HB et al. The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children. New Eng J Med 2001; 344:1263–1269.

    Article  PubMed  CAS  Google Scholar 

  77. Hormaeche CE, Khan CMA, Mastroeni P et al. Salmonella vaccines: mechanisms of immunity and their use as carriers of recombinant antigens. In: DAA Ala’Aldeen, Hormaeche CE, eds. Molecular and Clinical Aspects of Bacterial Vaccine Development. Chp 4. John Wiley and Sons Ltd, 1995:119–153.

    Google Scholar 

  78. Eisenstein TK, Huang D, Schwacha MG. Immunity to Salmonella infections. In: Paradise LJ, Bendinelli M, Friedman H, eds. Enteric Infections and Immunity. Chp 4. New York and London: Plenum Press, 1996:57–78.

    Google Scholar 

  79. Makela PH, Hormaeche CE. Immunity to Salmonella. In: S. Kaufmann, ed. Host Response to Intracellular Pathogens. Chapter 10. USA: RG Landers Co., 1996:143–166.

    Google Scholar 

  80. Harrison JA, Villarreal-Ramos B, Mastroeni P et al. Correlates of protection induced by live Aro-Salmonella typhimurium vaccines in the murine typhoid model. Immunology 1997; 90:618–625.

    Article  PubMed  CAS  Google Scholar 

  81. Nauciel C. Role of CD4+ T cells and T-independent mechanisms in acquired resistance to Salmonella typhimurium infection. J Immunol 1990; 145:1265–1269.

    PubMed  CAS  Google Scholar 

  82. Tite JP, Dougan G, Chatfield SN. The involvement of tumour necrosis factor in immunity to Salmonella infection. J Immunol 1991; 147:3161–316.

    PubMed  CAS  Google Scholar 

  83. Mastroeni P, Villarreal-Ramos B, Hormaeche CE. Role of T cells, TNFa and IFNg in recall of immunity to oral challenge with virulent salmonellae in mice vaccinated with live attenuated arosalmonella vaccines. Microbial Pathogen 1992; 13:477–491.

    Article  CAS  Google Scholar 

  84. Nauciel C, Espinasse-Maes F. Role of gamma interferon and tumor necrosis factoalpha in resistance to Salmonella typhimurium infection. Infect Immun 1992; 60:450–454.

    PubMed  CAS  Google Scholar 

  85. Schafer R, Eisenstein TK. Natural killer cells mediate protection induced by a Salmonella aroA mutant. Infect Immun 1992; 60:791–797.

    PubMed  CAS  Google Scholar 

  86. Mastroeni P, Harrison JA, Chabalgoity JA ET AL. Effect of interleukin 12 neutralisation on host resistance and gamma interferon production in mouse typhoid. Infect Immun 1996; 64:189–196.

    PubMed  CAS  Google Scholar 

  87. Levine MM, Herrington D, Murphy JR et al. Safety, infectivity, immunogenicity, and in vivo stability of two attenuated auxotrophic mutant variant strains of Salmonella typhi, 54lTy and 543Ty, as live oral vaccines in man. J Clin Invest 1987; 79:888–902.

    Article  PubMed  CAS  Google Scholar 

  88. Tacket CO, Hone DM, Losonsky GA et al. Clinical acceptability and immunogenicity of CVD908 Salmonella typhi vaccine strain. Vaccine 1992; 10:443–446.

    Article  PubMed  CAS  Google Scholar 

  89. Tacket CO, Hone DM, Curtis R III et al. Comparison of the safety and immunogenicity of DaroC DaroD and Dcya Dcrp Salmonella typhi strains in adult volunteers. Infect Immun 1992; 60:536–541.

    PubMed  CAS  Google Scholar 

  90. Tacket CO, Sztein MB, Losonsky GA et al. Safety of oral Salmonella typhi vaccine strains with deletions in htrA and aroC aroD and immune response in humans. Infect Immun 1997; 65:452–456.

    PubMed  CAS  Google Scholar 

  91. Hohmann EL, Oletta CA, Killeen KP et al. phoP/phoQ-deleted Salmonella typhi (Ty800) is a safe and immunogenic single-dose typhoid fever vaccine in volunteers. J Infect Dis 1996; 173:1408–1414.

    Article  PubMed  CAS  Google Scholar 

  92. Hohmann EL, Oletta CA, Miller SI. Evaluation of a phoP/phoQ-deleted, aroA-deleted live oral Salmonella typhi vaccine strain in human volunteers. Vaccine 1996; 14:19–24.

    Article  PubMed  CAS  Google Scholar 

  93. Dilts DA, Riesenfeld-Orn I, Fulginiti JP et al. Phase I clinical trials of aroA aroD and aroA aroD htrA attenuated S. typhi vaccines; effect of formulation of safety and immunogenicity. Vaccine 2000; 18:1473–1484.

    Article  PubMed  CAS  Google Scholar 

  94. Lowe DC, Savidge TC, Pickard D et al. Characterisation of candidate live oral Salmonella typhi vaccine strains harbouring defined mutations in aroA, aroC, and htrA. Infect Immun 1999; 67:700–707.

    PubMed  CAS  Google Scholar 

  95. Wang JY, Noriega FR, Galen JE et al. Constitutive expression of the Vi polysaccharide capsular antigen in attenuated Salmonella enterica serovar Typhi oral vaccine strain CDV 909. Infect Immun 2000; 68:4647–4652.

    Article  PubMed  CAS  Google Scholar 

  96. Hindle Z, Chatfield SN, Phillimore J et al. Characterisation in volunteers of Salmonella enterica derivatives harbouring defined aroA and SPI2 type III secretion system (ssaV) mutations. Infect Immun Submitted 2001.

    Google Scholar 

  97. Sztein MB, Wasserman SS, Tacket CO et al. Cytokine production patterns and lymphoproliferative responses in volunteers orally immunised with attenuated vaccine strains of Salmonella typhi. J Infect Dis. 1994; 170:1508–1517.

    Article  PubMed  CAS  Google Scholar 

  98. Cryz SJ, Furer E, Baron LS et al. Construction and characterisation of a Vi-positive variant of the Salmonella typhi live oral vaccine strain Ty21a. Infect Immun 1989; 57:3863–3868.

    PubMed  CAS  Google Scholar 

  99. Tacket CO, Losonsky G, Taylor DN et al. Lack of immune response to the Vi component of a Vi-positive variant of the Salmonella typhi live oral vaccine strain Ty21a in human studies. J Infect Dis 1991; 163:901–904.

    Article  PubMed  CAS  Google Scholar 

  100. Musher DM, Groover JE, Watson DA et al. Genetic regulation of the capacity to make immunoglobulin G to pneumococcal capsular polysaccharides. J Invest Med. 1997; 45:57–68.

    CAS  Google Scholar 

  101. Arya SC. Efficient vaccination strategy against typhoid fever. Vaccine 1997;18:2321.

    Google Scholar 

  102. Arya SC. Efficacy of Vi polysaccharide vaccine against Salmonella typhi. Vaccine 1999; 17:1015.

    Article  PubMed  CAS  Google Scholar 

  103. Keddy KH, Klugman KP, Robbins JB. Efficacy of Vi polysaccharide vaccine against strains of Salmonella typhi: reply. Vaccine 1998; 16:871–872.

    Article  PubMed  CAS  Google Scholar 

  104. Hormaeche CE. Letter to the editor. Vaccine 1999; 17:1016.

    Article  Google Scholar 

  105. Levine MM, Ferreccio C, Black RE et al. Progress in vaccines against typhoid fever. Rev Infect Dis 1989; 11:S552–S5667.

    Article  PubMed  Google Scholar 

Download references

Authors
  1. Deborah House
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gordon Dougan
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2003 Springer Science+Business Media New York

About this chapter

Cite this chapter

House, D., Dougan, G. (2003). Typhoid Vaccines. In: New Bacterial Vaccines. Medical Intelligence Unit. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-0053-7_21

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-0053-7_21

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-4902-0

  • Online ISBN: 978-1-4615-0053-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation